KEMPHARM, INC (KMPH) News Headlines

▮ More

Date

Headline

9/28/2022 9:03:20 AM KemPharm's Phase I Cardiovascular Safety Study Of Serdexmethylphenidate Yields Positive Results

9/28/2022 7:38:27 AM KemPharm Announces Positive Topline Data From Phase 1 Trial Evaluating Cardiovascular Safety Of Serdexmethylphenidate

12/20/2021 7:48:57 AM KemPharm Board Authorizes A Program To Repurchase Up To $50 Mln Of Stock

10/29/2021 6:13:59 AM Pre-market Movers: RVI, ABIO, ALF, ZEN, DBVT…

4/14/2021 10:37:31 AM Stock Alert: KemPharm Up 6%

3/4/2021 2:21:01 AM KMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

3/2/2021 11:46:12 PM KemPharm: FDA Approves AZSTARYS For Attention Deficit Hyperactivity Disorder In Patients Age Six Years And Older

11/10/2016 6:46:54 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) Q4 16 Estimate To -0.76 From -0.68

11/10/2016 6:46:28 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) 2018 Estimate To -1.92 From -1.85

11/10/2016 6:46:15 AM RBC Capital Markets Is Cutting KEMPHARM, INC (KMPH) 2017 Estimate To -2.93 From -2.83

11/10/2016 6:46:01 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) 2016 Estimate To -2.47 From -2.20

5/5/2016 6:32:22 PM FDA Panel Fails To Back Abuse-deterrent Properties Of KemPharm's Pain Pill

3/11/2016 8:00:46 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) FY18 Estimate To 0.72 From 0.76

3/11/2016 8:00:28 AM RBC Capital Markets Is Cutting KEMPHARM, INC (KMPH) FY17 Estimate To -2.53 From -1.97

3/11/2016 8:00:11 AM RBC Capital Markets Is Lowering KEMPHARM, INC (KMPH) FY16 Estimate To -3.14 From -2.23

Older Articles

Kempharm, Inc (KMPH)